REMARKS

The subject application is a divisional of U.S. Ser. No. 10/217,771, filed Aug. 13, 2002, which is a divisional of U.S. Ser. No. 09/582,513, filed Aug. 7, 2000, which is the National Stage of International application No. PCT/IB99/00617, filed April 8, 1999, which claims the benefit of provisional U.S. application Ser. No. 60/083,556, filed April 29, 1998, and is filed to pursue the invention of Group II, as set forth in the Restriction Requirement in the prior application. Applicant has inserted priority information on page 1 for the present application as required by 37 C.F.R. § 1.78.

Applicant has corrected a number of typographical and spelling errors on pages 1, 8 and 9, as specifically set forth above in the replacement paragraphs (marked-up versions of these amended paragraphs, as well as of the amended claims discussed below, are found in the Appendix attached hereto), *i.e.*, correcting the misspelling of "arrhythmias"; "barbiturates"; "amyotrophic" and the replacement of the incorrect term "progressive supramuscular palsy" with the correct term for the disorder "progressive supranuclear palsy". The term "obsessive-compulsive disorder is added to these paragraphs and has support on page 1. None of these amendments add new matter to the instant application.

In the parent application, the Examiner has set the restriction of the pending claims into Groups I, II, III, IV, V and VI in response to Applicant's traverse:

Group I (old Groups I, III and IX): corresponding in part to claims 1-10, 13 and 14, drawn to compounds, compositions, a method of use of formula I, wherein R² and R³ are open, *i.e.*, not forming/presenting a heterocyclic ring.

Group II (old Groups II, IV, and IX): corresponding in part to claims 1-10, 13 and 14, drawn to compounds, compositions, a method of use of formula I, wherein R² and R³ are closed, *i.e.*, form a non-heterocyclic ring.

Group III, IV, V and VI (old Groups V, VI, VII and VIII).

In the parent application, Applicant elected to prosecute Group III. Applicant now wishes to prosecute the invention of Group II, which subject matter has yet not been examined in the application.

If a telephone interview is deemed to be helpful to expedite the prosecution of the subject application, the Examiner is invited to contact applicant's undersigned attorney at the telephone number provided.

The Commissioner is hereby authorized to charge any fees required under 37 C.F.R. §§1.16 and 1.17 or to credit any overpayment to Deposit Account No. 16-1445.

Respectfully submitted,

Date: January 23, 2004

A. Dávid Joran Attorney for Applicant(s)

Reg. No. 37,858

Pfizer Inc Patent Department 150 East 42nd Street – 5th Floor New York, NY 10017-5755 (212) 733-3381